Langbahn Team – Weltmeisterschaft

LAE-32

LAE-32
Clinical data
Other namesLAE; Lysergic acid ethylamide; d-Lysergic acid ethylamide; d-Ethyllysergamide,
Routes of
administration		Oral
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal
Identifiers
  • (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21N3O
Molar mass295.386 g·mol−1
3D model (JSmol)
  • CCNC(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C)C2)c34
  • InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1 checkY
  • Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N checkY
  (verify)

D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine.[1][2] It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.

References

  1. ^ "N-Ethyllysergamide". PubChem. U.S. National Library of Medicine. Retrieved 2022-11-16.
  2. ^ Baquiran M, Al Khalili Y (2022). "Lysergic Acid Diethylamide Toxicity". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31985997. Retrieved 2022-11-18.


Quelle: https://en.wikipedia.org/wiki/LAE-32